ITGAM and neoplasm: Analogously, genetic deletion of integrin-αM (also known as CD11b) in mice resulted in decreased recruitment of PMN-MDSCs to colorectal carcinomas and led to reduced tumor burden and improved survival, establishing integrin-αM as an additional therapeutic target (228).